Neuronetics (STIM) Competitors $4.42 +0.03 (+0.68%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.43 +0.01 (+0.23%) As of 08/1/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock STIM vs. BLFS, TNDM, PLSE, MDXG, INMD, KMTS, SIBN, IRMD, EMBC, and BBNXShould you be buying Neuronetics stock or one of its competitors? The main competitors of Neuronetics include BioLife Solutions (BLFS), Tandem Diabetes Care (TNDM), Pulse Biosciences (PLSE), MiMedx Group (MDXG), InMode (INMD), Kestra Medical Technologies (KMTS), SiBone (SIBN), iRadimed (IRMD), Embecta (EMBC), and Beta Bionics (BBNX). These companies are all part of the "medical equipment" industry. Neuronetics vs. Its Competitors BioLife Solutions Tandem Diabetes Care Pulse Biosciences MiMedx Group InMode Kestra Medical Technologies SiBone iRadimed Embecta Beta Bionics BioLife Solutions (NASDAQ:BLFS) and Neuronetics (NASDAQ:STIM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership. Which has preferable earnings & valuation, BLFS or STIM? BioLife Solutions has higher revenue and earnings than Neuronetics. BioLife Solutions is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioLife Solutions$82.25M12.10-$20.18M-$0.29-71.76Neuronetics$74.89M3.90-$43.71M-$1.31-3.37 Do insiders & institutionals have more ownership in BLFS or STIM? 93.2% of BioLife Solutions shares are held by institutional investors. Comparatively, 53.6% of Neuronetics shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by insiders. Comparatively, 8.7% of Neuronetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more risk and volatility, BLFS or STIM? BioLife Solutions has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Comparatively, Neuronetics has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500. Is BLFS or STIM more profitable? BioLife Solutions has a net margin of -11.81% compared to Neuronetics' net margin of -53.67%. BioLife Solutions' return on equity of -0.66% beat Neuronetics' return on equity.Company Net Margins Return on Equity Return on Assets BioLife Solutions-11.81% -0.66% -0.58% Neuronetics -53.67%-174.15%-38.41% Does the media prefer BLFS or STIM? In the previous week, Neuronetics had 1 more articles in the media than BioLife Solutions. MarketBeat recorded 4 mentions for Neuronetics and 3 mentions for BioLife Solutions. Neuronetics' average media sentiment score of 0.88 beat BioLife Solutions' score of 0.76 indicating that Neuronetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLife Solutions 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neuronetics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer BLFS or STIM? BioLife Solutions presently has a consensus target price of $31.00, suggesting a potential upside of 48.97%. Neuronetics has a consensus target price of $5.50, suggesting a potential upside of 24.43%. Given BioLife Solutions' stronger consensus rating and higher possible upside, research analysts plainly believe BioLife Solutions is more favorable than Neuronetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLife Solutions 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Neuronetics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 SummaryBioLife Solutions beats Neuronetics on 11 of the 16 factors compared between the two stocks. Get Neuronetics News Delivered to You Automatically Sign up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STIM vs. The Competition Export to ExcelMetricNeuroneticsMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$290.24M$6.77B$5.47B$9.53BDividend YieldN/A1.32%4.74%4.08%P/E Ratio-3.3720.9428.6723.80Price / Sales3.9059.01422.3188.12Price / CashN/A20.5035.4557.96Price / Book7.754.468.275.55Net Income-$43.71M$174.54M$3.24B$259.03M7 Day Performance-1.56%-5.27%-3.63%-4.56%1 Month Performance29.24%-3.94%4.40%4.49%1 Year Performance145.56%8.26%25.97%18.05% Neuronetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STIMNeuronetics1.5217 of 5 stars$4.42+0.7%$5.50+24.4%+148.3%$290.24M$74.89M-3.37180Upcoming EarningsGap DownBLFSBioLife Solutions2.7847 of 5 stars$22.23-1.6%$31.00+39.5%-10.9%$1.08B$82.25M-76.65440Positive NewsTNDMTandem Diabetes Care3.5845 of 5 stars$16.84+6.0%$32.71+94.3%-56.3%$1.06B$940.20M-6.062,650Positive NewsUpcoming EarningsPLSEPulse Biosciences3.9173 of 5 stars$15.21+1.9%$22.00+44.6%-2.3%$1.00B$700K0.00140News CoverageMDXGMiMedx Group3.0778 of 5 stars$6.79+0.3%$11.50+69.4%+7.2%$999.94M$348.88M25.15870News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionINMDInMode3.0965 of 5 stars$14.54-1.2%$18.54+27.5%-17.1%$930.44M$394.82M6.24480News CoveragePositive NewsEarnings ReportAnalyst ForecastKMTSKestra Medical Technologies0.9765 of 5 stars$16.50-0.3%$27.33+65.7%N/A$849.82M$59.81M0.00300SIBNSiBone3.9258 of 5 stars$17.60+2.0%$22.50+27.8%+17.2%$735.10M$167.18M-27.50350Upcoming EarningsIRMDiRadimed4.1857 of 5 stars$57.11+1.4%$72.00+26.1%+43.4%$716.11M$73.24M36.85110News CoverageEarnings ReportDividend AnnouncementGap UpEMBCEmbecta4.6464 of 5 stars$11.33-3.4%$19.00+67.7%-35.3%$685.53M$1.12B12.592,100News CoverageUpcoming EarningsBBNXBeta Bionics2.3438 of 5 stars$13.99-5.7%$23.44+67.6%N/A$643.41M$65.12M0.00294Trending NewsEarnings ReportAnalyst ForecastLockup ExpirationAnalyst Revision Related Companies and Tools Related Companies BLFS Competitors TNDM Competitors PLSE Competitors MDXG Competitors INMD Competitors KMTS Competitors SIBN Competitors IRMD Competitors EMBC Competitors BBNX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STIM) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuronetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuronetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free STIM Stock Alerts